Psychemedics Corporation Reports Third Quarter 2023 Financial Results

ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023.

The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year.

The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Restructuring changes and related financial benefits will start to be realized in the fourth quarter and into fiscal year 2024. In addition, significant go-to-market improvements are in process led by the newly hired Chief Revenue Officer, Shannon Shoemaker, designed to evolve our pursuit of new verticals and improve our revenue growth in existing markets.

Gross margin percentage improved to 37% compared to 36% in third quarter of last year, as our cost reduction programs were able to offset the revenue decreases. Operating expenses increased 18% versus the comparable period last year in large part due to legal and settlement fees and third-party accounting and consulting fees. Also impacting the third quarter, the Company incurred costs related to appointment of the new CEO as announced on July 12, 2023. These charges are mostly non-recurring in nature and not expected to continue into fiscal year 2024. The Company also recorded a non-cash tax charge of $0.7 million as it was deemed more likely than not that the Company’s deferred tax assets will not be realized.

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Cautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In some cases, the reader can identify forward-looking statements by words such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict,”, or similar words. In particular, statements contained in this release that are not historical facts, including without limitation, statements concerning the impact of restructuring changes and go-to-market improvements and impact on future revenues may be “forward looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors to be taken into account in connection with such forward-looking statements include, but are not limited to, revenues, earnings, collections of receivables, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, including acceptance by the court of our wage/break settlement arrangement, general economic conditions, current and anticipated cash flows, available surplus, capital expenditure reserves required, debt service obligations, regulatory requirements, requirements under our bank loan agreements, and other factors that the Board of Directors of the Company may take into account. The forward-looking statements contained herein speak only of the Company’s expectations as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions, or circumstances on which any such statement is based.

The Psychemedics Corporation web site is

Investor Relations:

Phone: 978-206-8220

Psychemedics Corporation
Consolidated Statements of Operations
(in thousands, except per share amounts)
 Three Months Ended Nine Months Ended
 September 30, September 30,
  2023   2022   2023   2022 
Revenues$5,704  $6,516  $17,100  $19,537 
Cost of revenues 3,613   4,184   10,745   12,492 
Gross profit 2,091   2,332   6,355   7,045 
Operating expenses:       
General & administrative 2,200   1,588   5,291   4,360 
Marketing & selling 723   791   2,258   2,409 
Research & development 275   328   859   1,003 
Total Operating expenses 3,198   2,707   8,408   7,772 
Operating loss ( 1,107)  ( 375)  ( 2,053)  ( 727)
Other income (expense) :       
Settlement -   -   ( 500)  - 
Other -   ( 8)  ( 9)  49 
Total other income (expense), net -   ( 8)  ( 509)  49 
Loss before provision for (benefit from) income taxes ( 1,107)  ( 383)  ( 2,562)  ( 678)
Provision for (benefit from) income taxes 992   ( 286)  647   ( 282)
Net loss$(2,099) $(97) $(3,209) $(396)
Diluted net loss per share$(0.36) $(0.02) $(0.56) $(0.07)
Dividends declared per share$-  $0.07  $0.14  $0.14 

Psychemedics Corporation
Consolidated Balance Sheets
(in thousands, except par value)
 September 30, December 31,
  2023   2022 
Current Assets:   
Cash and cash equivalents$1,370  $4,750 
Accounts receivable, net of allowance for doubtful accounts 4,596   3,739 
Prepaid expenses and other current assets 1,524   1,136 
Income tax receivable 382   339 
Total Current Assets 7,872   9,964 
Fixed assets, net of accumulated amortization and depreciation 3,357   4,573 
Other assets 809   823 
Net deferred tax assets -   691 
Operating lease right-of-use assets 2,066   2,681 
Total Assets$14,104  $18,732 
Current Liabilities:   
Accounts payable$817  $448 
Accrued expenses 3,208   3,939 
Current portion of long-term debt 302   294 
Current portion of operating lease liabilities 1,058   1,037 
Total Current Liabilities 5,385   5,718 
Long-term debt 77   305 
Deferred tax liabilities, long-term 7   - 
Long-term portion of operating lease liabilities 1,206   1,938 
Total Liabilities 6,675   7,961 
Shareholders’ Equity:   
Common stock, $0.005 par value; 50,000 shares authorized; 6,470 and 6,349 shares issued and 5,802 and 5,681 shares outstanding, respectively 32   32 
Additional paid-in capital 34,941   34,275 
Less - Treasury stock, at cost, 668 shares ( 10,082)  ( 10,082)
Accumulated deficit ( 15,828)  ( 11,820)
Accumulated other comprehensive loss ( 1,634)  ( 1,634)
Total Shareholders’ Equity 7,429   10,771 
Total Liabilities and Shareholders’ Equity$14,104  $18,732 


2023 Q3 PR Backup